Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Work In Process (2016 - 2017)

Integra Lifesciences Holdings (IART) has disclosed Work In Process for 7 consecutive years, with $47.3 million as the latest value for Q3 2017.

  • Quarterly Work In Process changed N/A to $47.3 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $47.3 million through Sep 2017, changed N/A year-over-year, with the annual reading at $50.0 million for FY2016, N/A changed from the prior year.
  • Work In Process hit $47.3 million in Q3 2017 for Integra Lifesciences Holdings, down from $50.0 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $54.7 million in Q2 2015 to a low of $47.3 million in Q3 2017.
  • Historically, Work In Process has averaged $50.5 million across 4 years, with a median of $50.1 million in 2014.